At AACR: Chinese Biotech, Oncology Comms, and More

22 Apr 20264 min read0 viewsVerified Feed

GIST

You’re reading the web version of STAT’s popup newsletter, AACR in 30 seconds, your guide to what’s happening at the American Association of Cancer Researchers’ annual meeting. This is the last edition of our pop-up newsletter.

We hope you’ve learned as much as we have. If you’re not already a STAT+ subscriber, consider it!

There’s currently a  60% off promotion  on annual subscriptions. In the meantime, thanks for joining us.

Overcoming resistance and RevMed’s next drug? In case you missed it, Revolution Medicines’ sessions yesterday were jam-packed with conference attendees.

While most of the media coverage focused on the daraxonrasib in frontline pancreatic cancer data, the company also revealed some activity in a new compound, RM-055. CEO Mark Goldsmith described it as being part of a new class of “catalytic inhibitors,” since it can slice off a phosphate from GTP-RAS, or the “on” form of RAS, and turn the protein off.

Clinical Editorial

Context and scope

This piece is a brief conference newsletter item from STAT’s pop-up series covering the American Association for Cancer Research annual meeting.

It is presented as the final edition of that pop-up newsletter and notes a promotional subscription offer for STAT+; no systematic study data or methods are provided in the source beyond conference reporting.

Key conference highlight — Revolution Medicines sessions

Revolution Medicines drew large attendance at its sessions.
Media attention focused on daraxonrasib data in frontline pancreatic cancer (no detailed results reported in the source).
The company also presented information on a new compound designated RM-055.

Mechanistic description reported

RM-055 was described by CEO Mark Goldsmith as belonging to a purported new class termed “catalytic inhibitors.”
The mechanism attributed to RM-055 in the source is removal of a phosphate from GTP-bound RAS (the active “on” form), thereby converting RAS to an inactive state.
The report frames this catalytic activity as enabling a single molecule to inactivate multiple mutant RAS proteins.

Rationale and rationale-linked interest

The article explains that one mechanism by which tumors develop resistance to RAS inhibitors is amplification of mutant RAS, increasing the abundance of the active oncoprotein.
RM-055’s described catalytic mechanism was presented as potentially addressing that resistance mechanism by inactivating multiple RAS molecules rather than relying on stoichiometric inhibition.

Limitations and missing details

The source does not provide preclinical or clinical data, quantitative results, pharmacology, safety information, or independent verification of the mechanism.